PL1620072T3 - Zawierająca cynk kompozycja o przedłużonym uwalnianiu, produkt leczniczy i sposób jego wytwarzania - Google Patents

Zawierająca cynk kompozycja o przedłużonym uwalnianiu, produkt leczniczy i sposób jego wytwarzania

Info

Publication number
PL1620072T3
PL1620072T3 PL04725163T PL04725163T PL1620072T3 PL 1620072 T3 PL1620072 T3 PL 1620072T3 PL 04725163 T PL04725163 T PL 04725163T PL 04725163 T PL04725163 T PL 04725163T PL 1620072 T3 PL1620072 T3 PL 1620072T3
Authority
PL
Poland
Prior art keywords
zinc
release composition
containing sustained
sustained
preparation
Prior art date
Application number
PL04725163T
Other languages
English (en)
Inventor
Michio Kimura
Tomoko Eto
Yutaka Mizushima
Original Assignee
Ltt Bio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltt Bio Pharma Co Ltd filed Critical Ltt Bio Pharma Co Ltd
Publication of PL1620072T3 publication Critical patent/PL1620072T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04725163T 2003-05-01 2004-04-01 Zawierająca cynk kompozycja o przedłużonym uwalnianiu, produkt leczniczy i sposób jego wytwarzania PL1620072T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003126503 2003-05-01
PCT/JP2004/004791 WO2004096179A1 (en) 2003-05-01 2004-04-01 Zinc-containing sustained-release composition, its preparation, and method for producing the same
EP04725163A EP1620072B1 (en) 2003-05-01 2004-04-01 Zinc-containing sustained-release composition, its preparation, and method for producing the same

Publications (1)

Publication Number Publication Date
PL1620072T3 true PL1620072T3 (pl) 2008-10-31

Family

ID=33410296

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04725163T PL1620072T3 (pl) 2003-05-01 2004-04-01 Zawierająca cynk kompozycja o przedłużonym uwalnianiu, produkt leczniczy i sposób jego wytwarzania

Country Status (9)

Country Link
US (1) US7642230B2 (pl)
EP (1) EP1620072B1 (pl)
JP (1) JP4567668B2 (pl)
CN (1) CN100364499C (pl)
AT (1) ATE390126T1 (pl)
DE (1) DE602004012731T2 (pl)
ES (1) ES2300758T3 (pl)
PL (1) PL1620072T3 (pl)
WO (1) WO2004096179A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US20100022457A1 (en) * 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
JP2009256241A (ja) * 2008-04-16 2009-11-05 Galenisearch Laboratories Inc 生理活性蛋白質含有ナノ粒子組成物およびその製造方法
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
CN110742065B (zh) * 2019-10-25 2021-07-27 山东农业大学 一种纳米花负载农药制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15737A (en) * 1856-09-16 Mode of attaching- shafts to sleighs
CA2150803C (en) * 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
PT779806E (pt) * 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
WO1997007788A2 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
EP0910402B1 (en) * 1996-06-20 2007-08-08 Novo Nordisk A/S Insulin preparations containing mannitol
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
JP2002348234A (ja) 2001-05-28 2002-12-04 Purotekku:Kk 薬物封入無機物微粒子、その製造法及び薬物封入無機物微粒子製剤
JP4460892B2 (ja) * 2001-06-21 2010-05-12 ジェネンテック インコーポレイテッド 徐放性組成物
JP2003081865A (ja) 2001-09-12 2003-03-19 Ltt Institute Co Ltd 水不溶性徐放性組成物、その製剤及びその製造方法

Also Published As

Publication number Publication date
EP1620072B1 (en) 2008-03-26
DE602004012731D1 (de) 2008-05-08
EP1620072A1 (en) 2006-02-01
ES2300758T3 (es) 2008-06-16
CN1780607A (zh) 2006-05-31
US7642230B2 (en) 2010-01-05
JP4567668B2 (ja) 2010-10-20
CN100364499C (zh) 2008-01-30
ATE390126T1 (de) 2008-04-15
WO2004096179A1 (en) 2004-11-11
DE602004012731T2 (de) 2009-04-09
JP2006525319A (ja) 2006-11-09
US20060210629A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
YU59704A (sh) Farmaceutske formulacije derivata platine
MX2007007458A (es) Derivados de quinazolina para inhibir crecimiento de celulas cancerigenas y metodo para la preparacion de los mismos.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
JP2013542961A (ja) 生理活性物質の性質を調節するビスマス含有化合物
MXPA05012901A (es) Composiciones topicas estables, claras, de claritromicina y procesos para su preparacion.
CA2468314A1 (en) The use of water-soluble lamarin in the treatment of cancer
IL152479A (en) Pharmaceutical form for giving peptides, methods for making and using it
SI1594885T1 (sl) Zdravilo za inhibiranje rasti tumorjev
RU2007103154A (ru) Адсорбент фосфата на основе сульфата железа
EP0270026A3 (en) Pharmaceutical preparation comprising vitamin b6
MXPA05003318A (es) Forma de administracion para peptidos farmaceuticamente activos con liberacion sostenida y metodo para la produccion de los mismos.
DE60213395D1 (de) Chitosan-komplex zur krebsbehandlung unter bildung von autoaggregaten und herstellungsverfahren dafür
PL1620072T3 (pl) Zawierająca cynk kompozycja o przedłużonym uwalnianiu, produkt leczniczy i sposób jego wytwarzania
CA2388395A1 (en) Compound
WO2010071320A3 (ko) 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
UA83888C2 (ru) Фармацевтическая композиция винфлунина, предназначенная для парентерального введения, способ получения и применение
RU2011130508A (ru) Рецептура для перорального трансмукозального применения гиполипидемических лекарственных средств
SG146687A1 (en) Drug containing (2r)-2-propyloctanoic acid as the active ingredient
MX2025013245A (es) Compuesto de camptotecina deuterado, preparacion y uso de este
ATE357454T1 (de) Verfahren zur herstellung tryptophanreicher peptide
EP1634585A4 (en) MEDICINAL PRODUCTS CONTAINING DELAYED MICROTEIL, PROCESS FOR ITS PREPARATION AND MICROPARTICLE CONTAINING PREPARATION
US7893212B2 (en) S-nitroso group-containing albumin, method for production, and anticancer agent
CA3168207A1 (en) Cellular uptake
CA2531620A1 (en) Cancer combination therapy comprising azd2171 and zd1839
WO2007018585A3 (en) Process for controlling protein to salt ratio in animal muscle protein composition and protein composition